Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial
Primary resultResult — go to the resultOdds ratio 2.9 95% CI 1.4–6.4Authors' conclusion
Among patients with lymphoma treated with anthracycline-based chemotherapy, atorvastatin reduced the incidence of cardiac dysfunction.
Study context
- Population
- Patients with lymphoma scheduled to receive anthracycline-based chemotherapy286 (95%) completed
- Participants
- 300 patients
- Comparison
- Atorvastatin vs placebo
- Atorvastatinn = 150
- Placebon = 150reference
- Primary endpoint
- Absolute decline in left ventricular ejection fraction (LVEF) of ≥10% from prior to chemotherapy to a final value of <55%
- Follow-up
- 12 months
Methodological detailsdouble-blind, placebo-controlled, multicentre (9 academic medical centres, US and Canada)
- Double-blind
- Placebo-controlled
- Multicentre (9 academic medical centres, US and Canada)
Primary result
As reported in the abstract
Odds ratio
2.9
95% CI 1.4–6.4
P = 0.002
Events by treatment group
Placebo vs Atorvastatin
OR 2.9 (95% CI 1.4–6.4); P = 0.002
Secondary outcomes
Absolute LVEF decline ≥5% to a final value <55% · 12 months
P = 0.001
Incident HF · 24 months
P = 0.26
- Incident HF: 13 adjudicated HF events (4%) overall
Safety
Serious related adverse events
- Low and similar between groups
Original publication
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial. JAMA. Published 8 August 2023. doi:10.
Summarised from the published abstract; every number is checked against it